Download App

Log in to access Online Inquiry
Company Overview More
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CEO: Hershberg M.D., Ph.D., Robert M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > HLVX HilleVax > Detailed Quotes

HLVX HilleVax

10.170-1.120-9.92%
Close 05/20 20:00 ET
10.17000.00%
Post Mkt Price 05/20 16:00 ET
High
13.520
Open
10.530
Turnover
1.68M
Low
9.840
Pre Close
11.290
Volume
156.16K
Market Cap
307.05M
P/E(TTM)
Loss
52wk High
20.950
Shares
30.19M
P/E(Static)
Loss
52wk Low
9.840
Float Cap
104.69M
Bid/Ask %
33.33%
Historical High
20.950
Shs Float
10.29M
Volume Ratio
0.77
Historical Low
9.840
Dividend TTM
--
Div Yield TTM
--
P/B
-3.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.52%
Amplitude
32.59%
Avg Price
10.756
Lot Size
1
Float Cap
104.69M
Bid/Ask %
33.33%
Historical High
20.950
Shs Float
10.29M
Volume Ratio
0.77
Historical Low
9.840
Dividend TTM
--
P/B
-3.05
Dividend LFY
--
Turnover Ratio
1.52%
Amplitude
32.59%
Avg Price
10.756
Lot Size
1
Price Forecast

No Data

News

Comment